CA2946115A1 - Methods and compositions for treatment of lipid storage disorders - Google Patents

Methods and compositions for treatment of lipid storage disorders Download PDF

Info

Publication number
CA2946115A1
CA2946115A1 CA2946115A CA2946115A CA2946115A1 CA 2946115 A1 CA2946115 A1 CA 2946115A1 CA 2946115 A CA2946115 A CA 2946115A CA 2946115 A CA2946115 A CA 2946115A CA 2946115 A1 CA2946115 A1 CA 2946115A1
Authority
CA
Canada
Prior art keywords
cells
pkc
npc1
vimentin
bryostatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2946115A
Other languages
English (en)
French (fr)
Inventor
Yiannis A. Ioannou
Lawrence ALTSTIEL
David R. Crockford
Sathapana Kongsamut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
TAO Synergies Inc
Original Assignee
Icahn School of Medicine at Mount Sinai
Neurotrope Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai, Neurotrope Bioscience Inc filed Critical Icahn School of Medicine at Mount Sinai
Publication of CA2946115A1 publication Critical patent/CA2946115A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CA2946115A 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders Abandoned CA2946115A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461981473P 2014-04-18 2014-04-18
US61/981,473 2014-04-18
US201461987360P 2014-05-01 2014-05-01
US61/987,360 2014-05-01
PCT/US2015/025821 WO2015160851A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Publications (1)

Publication Number Publication Date
CA2946115A1 true CA2946115A1 (en) 2015-10-22

Family

ID=54321042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2946115A Abandoned CA2946115A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Country Status (9)

Country Link
US (3) US20170172978A1 (https=)
EP (1) EP3131543A4 (https=)
JP (1) JP2017511387A (https=)
KR (1) KR20170031653A (https=)
CN (1) CN107072982A (https=)
CA (1) CA2946115A1 (https=)
IL (1) IL248494A0 (https=)
MX (1) MX2016013680A (https=)
WO (1) WO2015160851A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
AU2019255739A1 (en) * 2018-04-20 2020-11-12 Biojiva Llc Stabilized polyunsaturated compounds and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040214A1 (en) 1999-11-30 2001-06-07 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
KR20050094761A (ko) 2002-07-02 2005-09-28 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 브리오스타틴형 화합물을 사용한 ｓＡＰＰα 분비의 증진및 인지 개선을 위한 수단으로서의 ＰＫＣ 활성화
US8497385B2 (en) 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009099563A2 (en) * 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
WO2010014585A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
WO2011019763A2 (en) * 2009-08-10 2011-02-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
JP6422778B2 (ja) * 2011-11-13 2018-11-14 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｐｋｃアクチベーターおよびその組合せ
EP3122351A1 (en) * 2014-03-27 2017-02-01 Daniel L. Alkon Compositions and methods to treat niemann-pick disease

Also Published As

Publication number Publication date
EP3131543A1 (en) 2017-02-22
EP3131543A4 (en) 2017-12-20
IL248494A0 (en) 2016-12-29
US20170172978A1 (en) 2017-06-22
US20190201377A1 (en) 2019-07-04
US9724328B2 (en) 2017-08-08
KR20170031653A (ko) 2017-03-21
WO2015160851A1 (en) 2015-10-22
CN107072982A (zh) 2017-08-18
US20150297559A1 (en) 2015-10-22
JP2017511387A (ja) 2017-04-20
MX2016013680A (es) 2017-07-05

Similar Documents

Publication Publication Date Title
Jeon et al. Physiological and pathological roles of lipogenesis
Hammerschmidt et al. Contribution of specific ceramides to obesity-associated metabolic diseases
Lone et al. 1-Deoxysphingolipids
Renvoisé et al. Reep1 null mice reveal a converging role for hereditary spastic paraplegia proteins in lipid droplet regulation
Jacobs et al. Hepatic CTP: phosphocholine cytidylyltransferase-α is a critical predictor of plasma high density lipoprotein and very low density lipoprotein
Takasugi et al. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate
Sassa et al. A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells
Podbielska et al. Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis
JP2016535725A (ja) 脂質異常症の予防または治療のための化合物および該化合物を含む組成物
Tamari et al. PKC activation in Niemann pick C1 cells restores subcellular cholesterol transport
Knapp et al. Decreased free sphingoid base concentration in the plasma of patients with chronic systolic heart failure
Garcia-Gil et al. Nuclear lipids in the nervous system: what they do in health and disease
Deevska et al. Novel interconnections in lipid metabolism revealed by overexpression of sphingomyelin synthase-1
US20190201377A1 (en) Methods and compositions for treatment of lipid storage disorders
Kitatani et al. Mechanism of inhibition of sequestration of protein kinase C α/βII by ceramide: Roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C α/βII on threonine 638/641
Harasim-Symbor et al. Additive effects of dexamethasone and palmitate on hepatic lipid accumulation and secretion
Nakamura et al. Sphingomyelin regulates the activity of secretory phospholipase A2 in the plasma membrane
Baranowski et al. Pioglitazone induces de novo ceramide synthesis in the rat heart
Bandet et al. CERT-Dependent ceramide transport, a crucial process in cells
AU2022283770B2 (en) Cyclic plasmenylethanolamines
Yamada et al. Role of canonical and Non-Canonical sphingolipids and their metabolic enzymes in bone health
US20050182020A1 (en) Ceramide de novo synthesis-based therapeutic and prophylactic methods, and related articles of manufacture
Liu et al. Impaired synaptic vesicle recycling contributes to presynaptic dysfunction in lipoprotein lipase-deficient mice
Leonelli et al. TRP channels, omega-3 fatty acids, and oxidative stress in neurodegeneration: from the cell membrane to intracellular cross-links
Al Saedi et al. Osteosarcopenia as a lipotoxic disease

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123